Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MLYS

Mineralys Therapeutics Inc

Apr 26 • 04:00PM ET

11.87

Dollar change +0.83
Percentage change 7.52	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB VTWO HRTS SCHA IWO IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.77	Insider Own	53.37%	Shs Outstand	41.13M	Perf Week	5.14%
Market Cap	589.11M	Forward P/E	-	EPS next Y	-2.88	Insider Trans	2.16%	Shs Float	23.14M	Perf Month	-7.12%
Income	-71.90M	PEG	-	EPS next Q	-0.67	Inst Own	39.81%	Short Float	3.77%	Perf Quarter	15.24%
Sales	0.00M	P/S	-	EPS this Y	-29.48%	Inst Trans	-	Short Ratio	5.09	Perf Half Y	45.11%
Book/sh	5.86	P/B	2.02	EPS next Y	-11.85%	ROA	-39.28%	Short Interest	0.87M	Perf Year	-7.70%
Cash/sh	4.77	P/C	2.49	EPS next 5Y	-	ROE	-41.38%	52W Range	5.85 - 17.70	Perf YTD	38.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-29.81%	52W High	-32.94%	Beta	2.35
Dividend TTM	-	Quick Ratio	23.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	102.91%	ATR (14)	0.67
Dividend Ex-Date	-	Current Ratio	23.76	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	45.78	Volatility	4.70% 4.96%
Employees	28	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	33.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-173.89%	Payout	-	Rel Volume	0.38	Prev Close	11.04
Sales Surprise	-	EPS Surprise	26.06%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	171.50K	Price	11.87
SMA20	-3.42%	SMA50	-11.43%	SMA200	7.47%	Trades		Volume	65,808	Change	7.52%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Buy	$30
Mar-07-23	Initiated	Wells Fargo	Overweight	$27
Mar-07-23	Initiated	Stifel	Buy	$45
Mar-07-23	Initiated	Guggenheim	Buy	$32
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Credit Suisse	Outperform	$40
Mar-07-23	Initiated	BofA Securities	Buy	$39

Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-22-24 10:51AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-21-24 11:53AM	MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
09:11AM	Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... (GuruFocus.com)
07:00AM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:05PM	Loading…
Mar-13-24 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 (GlobeNewswire)
Feb-08-24 08:00AM	Mineralys Therapeutics Announces $120 Million Private Placement Financing (GlobeNewswire) +12.51%
Jan-29-24 04:05PM	Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference (GlobeNewswire) +6.21%
Jan-17-24 12:00PM	Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-04-24 04:05PM	Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer (GlobeNewswire)
Dec-21-23 04:05PM	Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension (GlobeNewswire)
Nov-12-23 09:22AM	Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-11-23 11:30AM	Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023 (GlobeNewswire)
Nov-09-23 04:05PM	Mineralys Therapeutics to Participate in Three Upcoming Conferences (GlobeNewswire) -9.31%
Nov-07-23 05:12PM	Mineralys Therapeutics Inc (MLYS) Reports Q3 2023 Financials; R&D Expenses Rise Amid ... (GuruFocus.com) +8.02%
04:05PM	Loading…
04:05PM	Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 10:00AM	Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting (GlobeNewswire)
Oct-31-23 04:05PM	Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023 (GlobeNewswire)
Oct-13-23 04:10PM	Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023 (GlobeNewswire) +5.59%
Sep-19-23 04:00PM	Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy (GlobeNewswire)
Sep-14-23 04:05PM	Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas (GlobeNewswire)
Sep-11-23 04:05PM	Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023 (GlobeNewswire)
Sep-10-23 07:47AM	Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension (GlobeNewswire)
07:45AM	Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire)
Sep-09-23 05:00AM	CEO Jon Congleton Buys 2,250 Shares of Mineralys Therapeutics Inc (MLYS) (GuruFocus.com)
Sep-05-23 04:05PM	Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions (GlobeNewswire) -5.57%
09:55AM	Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High? (Zacks)
Aug-29-23 04:05PM	Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 (GlobeNewswire)
Aug-22-23 05:45PM	Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.84%
Aug-07-23 04:05PM	Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.02%
04:05PM	Loading…
Jul-31-23 04:05PM	Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023 (GlobeNewswire)
Jul-17-23 04:01PM	Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD) (GlobeNewswire)
Jun-09-23 08:04AM	10 Struggling IPOs To Buy For The Long-Term (Insider Monkey)
May-31-23 08:00AM	Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-15-23 04:01PM	Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 08:39AM	We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth (Simply Wall St.)
May-02-23 08:00AM	Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension (GlobeNewswire)
May-01-23 08:00AM	Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023 (GlobeNewswire)
Apr-27-23 04:47PM	Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023 (GlobeNewswire)
Mar-15-23 04:01PM	Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-04-23 04:30PM	Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC (GlobeNewswire)
Mar-01-23 04:05PM	Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023 (GlobeNewswire)
Feb-20-23 08:00AM	Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023 (GlobeNewswire)
Feb-17-23 12:08PM	Lab Notes: AnPac dips into real estate with diversification strategy; Mineralys closes $220.8M IPO (American City Business Journals)
Feb-14-23 04:01PM	Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-23 05:16PM	Mineralys, Enlight Trading Debuts Add to Big Week for US IPOs (Bloomberg)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rodman David Malcom	Chief Medical Officer	Apr 12 '24	Option Exercise	1.08	6,349	6,857	66,997	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Apr 11 '24	Option Exercise	0.54	5,017	2,709	60,648	Apr 15 04:24 PM
Rodman David Malcom	Chief Medical Officer	Mar 12 '24	Option Exercise	1.08	6,348	6,856	55,631	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Mar 11 '24	Option Exercise	0.54	5,017	2,709	49,283	Mar 13 05:35 PM
Rodman David Malcom	Chief Medical Officer	Feb 12 '24	Option Exercise	0.84	11,366	9,566	44,266	Feb 13 04:08 PM
Samsara BioCapital GP, LLC	10% Owner	Feb 12 '24	Buy	13.50	555,555	7,499,992	5,074,916	Feb 14 09:06 PM
Rodman David Malcom	Chief Medical Officer	Jan 12 '24	Option Exercise	1.08	6,348	6,856	32,900	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Jan 11 '24	Option Exercise	0.54	5,017	2,709	26,552	Jan 12 04:01 PM
Rodman David Malcom	Chief Medical Officer	Dec 11 '23	Option Exercise	0.54	5,018	2,710	20,069	Dec 12 05:08 PM
Congleton Jon	Chief Executive Officer	Nov 22 '23	Buy	5.97	4,250	25,356	1,049,068	Nov 27 04:01 PM
Rodman David Malcom	Chief Medical Officer	Nov 13 '23	Option Exercise	0.54	5,017	2,709	15,051	Nov 14 06:18 PM
Rodman David Malcom	Chief Medical Officer	Nov 03 '23	Option Exercise	0.54	10,034	5,418	10,034	Nov 07 05:15 PM
Congleton Jon	Chief Executive Officer	Sep 06 '23	Buy	12.08	2,250	27,180	1,044,818	Sep 08 08:49 AM
Congleton Jon	Chief Executive Officer	Aug 17 '23	Buy	12.10	2,250	27,225	1,042,568	Aug 21 04:03 PM
Rodman David Malcom	Chief Medical Officer	Aug 11 '23	Option Exercise	0.80	157,091	125,967	80,909	Aug 11 07:11 PM
Congleton Jon	Chief Executive Officer	Aug 11 '23	Buy	12.89	2,000	25,780	1,040,318	Aug 11 07:11 PM
Rodman David Malcom	Chief Medical Officer	Aug 11 '23	Sale	12.81	157,091	2,012,336	0	Aug 11 07:11 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '23	Option Exercise	0.54	74,625	40,298	74,625	Aug 11 07:11 PM
Rodman David Malcom	Chief Medical Officer	Aug 10 '23	Sale	13.16	74,625	982,065	0	Aug 11 07:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MLYS

Mineralys Therapeutics Inc

Upgrade your FINVIZ experience